Skip to main content
Erschienen in: The Cerebellum 2/2010

01.06.2010

Cellular and Molecular Pathways Triggering Neurodegeneration in the Spinocerebellar Ataxias

verfasst von: Antoni Matilla-Dueñas, Ivelisse Sánchez, Marc Corral-Juan, Antoni Dávalos, Ramiro Alvarez, Pilar Latorre

Erschienen in: The Cerebellum | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. To date, more than 30 genes have been identified triggering the well-described clinical and pathological phenotype, but the underlying cellular and molecular events are still poorly understood. Studies of the functions of the proteins implicated in SCAs and the corresponding altered cellular pathways point to major aetiological roles for defects in transcriptional regulation, protein aggregation and clearance, alterations of calcium homeostasis, and activation of pro-apoptotic routes among others, all leading to synaptic neurotransmission deficits, spinocerebellar dysfunction, and, ultimately, neuronal demise. However, more mechanistic and detailed insights are emerging on these molecular routes. The growing understanding of how dysregulation of these pathways trigger the onset of symptoms and mediate disease progression is leading to the identification of conserved molecular targets influencing the critical pathways in pathogenesis that will serve as effective therapeutic strategies in vivo, which may prove beneficial in the treatment of SCAs. Herein, we review the latest evidence for the proposed cellular and molecular processes to the pathogenesis of dominantly inherited spinocerebellar ataxias and the ongoing therapeutic strategies.
Literatur
1.
Zurück zum Zitat Matilla-Dueñas A, Goold R, Giunti P (2006) Molecular pathogenesis of spinocerebellar ataxias. Brain 129:1357–1370CrossRef Matilla-Dueñas A, Goold R, Giunti P (2006) Molecular pathogenesis of spinocerebellar ataxias. Brain 129:1357–1370CrossRef
2.
Zurück zum Zitat Tsuji S, Onodera O, Goto J, Nishizawa M (2008) Sporadic ataxias in Japan—a population-based epidemiological study. Cerebellum 7:189–197PubMedCrossRef Tsuji S, Onodera O, Goto J, Nishizawa M (2008) Sporadic ataxias in Japan—a population-based epidemiological study. Cerebellum 7:189–197PubMedCrossRef
3.
Zurück zum Zitat Schols L, Peters S, Szymanski S, Kruger R, Lange S, Hardt C et al (2000) Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 57:1495–1500PubMedCrossRef Schols L, Peters S, Szymanski S, Kruger R, Lange S, Hardt C et al (2000) Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 57:1495–1500PubMedCrossRef
4.
Zurück zum Zitat Riess O, Rub U, Pastore A, Bauer P, Schols L (2008) SCA3: neurological features, pathogenesis and animal models. Cerebellum 7:125–137PubMedCrossRef Riess O, Rub U, Pastore A, Bauer P, Schols L (2008) SCA3: neurological features, pathogenesis and animal models. Cerebellum 7:125–137PubMedCrossRef
5.
Zurück zum Zitat Wang YG, Du J, Wang JL, Chen J, Chen C, Luo YY et al (2009) Six cases of SCA3/MJD patients that mimic hereditary spastic paraplegia in clinic. J Neurol Sci 285:121–124PubMedCrossRef Wang YG, Du J, Wang JL, Chen J, Chen C, Luo YY et al (2009) Six cases of SCA3/MJD patients that mimic hereditary spastic paraplegia in clinic. J Neurol Sci 285:121–124PubMedCrossRef
6.
Zurück zum Zitat Gan SR, Zhao K, Wu ZY, Wang N, Murong SX (2009) Chinese patients with Machado-Joseph disease presenting with complicated hereditary spastic paraplegia. Eur J Neurol 16:953–956PubMedCrossRef Gan SR, Zhao K, Wu ZY, Wang N, Murong SX (2009) Chinese patients with Machado-Joseph disease presenting with complicated hereditary spastic paraplegia. Eur J Neurol 16:953–956PubMedCrossRef
7.
Zurück zum Zitat Lukas C, Hahn HK, Bellenberg B, Hellwig K, Globas C, Schimrigk SK et al (2008) Spinal cord atrophy in spinocerebellar ataxia type 3 and 6: impact on clinical disability. J Neurol 255:1244–1249PubMedCrossRef Lukas C, Hahn HK, Bellenberg B, Hellwig K, Globas C, Schimrigk SK et al (2008) Spinal cord atrophy in spinocerebellar ataxia type 3 and 6: impact on clinical disability. J Neurol 255:1244–1249PubMedCrossRef
8.
Zurück zum Zitat Tan EK, Tong J, Pavanni R, Wong MC, Zhao Y (2007) Genetic analysis of SCA 2 and 3 repeat expansions in essential tremor and atypical Parkinsonism. Mov Disord 22:1971–1974PubMedCrossRef Tan EK, Tong J, Pavanni R, Wong MC, Zhao Y (2007) Genetic analysis of SCA 2 and 3 repeat expansions in essential tremor and atypical Parkinsonism. Mov Disord 22:1971–1974PubMedCrossRef
9.
Zurück zum Zitat Reimold M, Globas C, Gleichmann M, Schulze M, Gerloff C, Bares R et al (2006) Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography. Mov Disord 21:1667–1673PubMedCrossRef Reimold M, Globas C, Gleichmann M, Schulze M, Gerloff C, Bares R et al (2006) Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography. Mov Disord 21:1667–1673PubMedCrossRef
10.
Zurück zum Zitat Friedman JH, Fernandez HH, Sudarsky LR (2003) REM behavior disorder and excessive daytime somnolence in Machado–Joseph disease (SCA-3). Mov Disord 18:1520–1522PubMedCrossRef Friedman JH, Fernandez HH, Sudarsky LR (2003) REM behavior disorder and excessive daytime somnolence in Machado–Joseph disease (SCA-3). Mov Disord 18:1520–1522PubMedCrossRef
11.
Zurück zum Zitat Pradhan C, Yashavantha BS, Pal PK, Sathyaprabha TN (2008) Spinocerebellar ataxias type 1, 2 and 3: a study of heart rate variability. Acta Neurol Scand 117:337–342PubMedCrossRef Pradhan C, Yashavantha BS, Pal PK, Sathyaprabha TN (2008) Spinocerebellar ataxias type 1, 2 and 3: a study of heart rate variability. Acta Neurol Scand 117:337–342PubMedCrossRef
12.
Zurück zum Zitat van de Warrenburg BP, Notermans NC, Schelhaas HJ, van Alfen N, Sinke RJ, Knoers NV et al (2004) Peripheral nerve involvement in spinocerebellar ataxias. Arch Neurol 61:257–261PubMedCrossRef van de Warrenburg BP, Notermans NC, Schelhaas HJ, van Alfen N, Sinke RJ, Knoers NV et al (2004) Peripheral nerve involvement in spinocerebellar ataxias. Arch Neurol 61:257–261PubMedCrossRef
13.
Zurück zum Zitat Burk K, Globas C, Bosch S, Klockgether T, Zuhlke C, Daum I et al (2003) Cognitive deficits in spinocerebellar ataxia type 1, 2, and 3. J Neurol 250:207–211PubMedCrossRef Burk K, Globas C, Bosch S, Klockgether T, Zuhlke C, Daum I et al (2003) Cognitive deficits in spinocerebellar ataxia type 1, 2, and 3. J Neurol 250:207–211PubMedCrossRef
14.
Zurück zum Zitat Gupta SN, Marks HG (2008) Spinocerebellar ataxia type 7 mimicking Kearns–Sayre syndrome: a clinical diagnosis is desirable. J Neurol Sci 264:173–176PubMedCrossRef Gupta SN, Marks HG (2008) Spinocerebellar ataxia type 7 mimicking Kearns–Sayre syndrome: a clinical diagnosis is desirable. J Neurol Sci 264:173–176PubMedCrossRef
15.
Zurück zum Zitat Wardle M, Morris HR, Robertson NP (2009) Clinical and genetic characteristics of non-Asian dentatorubral-pallidoluysian atrophy: a systematic review. Mov Disord 24:1636–1640PubMedCrossRef Wardle M, Morris HR, Robertson NP (2009) Clinical and genetic characteristics of non-Asian dentatorubral-pallidoluysian atrophy: a systematic review. Mov Disord 24:1636–1640PubMedCrossRef
16.
Zurück zum Zitat Matilla-Dueñas A (2008) The highly heterogeneous spinocerebellar ataxias: from genes to targets for therapeutic intervention. Cerebellum 7:97–100PubMedCrossRef Matilla-Dueñas A (2008) The highly heterogeneous spinocerebellar ataxias: from genes to targets for therapeutic intervention. Cerebellum 7:97–100PubMedCrossRef
17.
Zurück zum Zitat Holmes SE, O'Hearn EE, McInnis MG, Gorelick-Feldman DA, Kleiderlein JJ, Callahan C et al (1999) Expansion of a novel CAG trinucleotide repeat in the 5′ region of PPP2R2B is associated with SCA12. Nat Genet 23:391–392PubMedCrossRef Holmes SE, O'Hearn EE, McInnis MG, Gorelick-Feldman DA, Kleiderlein JJ, Callahan C et al (1999) Expansion of a novel CAG trinucleotide repeat in the 5′ region of PPP2R2B is associated with SCA12. Nat Genet 23:391–392PubMedCrossRef
18.
Zurück zum Zitat Wakamiya M, Matsuura T, Liu Y, Schuster GC, Gao R, Xu W et al (2006) The role of ataxin 10 in the pathogenesis of spinocerebellar ataxia type 10. Neurology 67:607–613PubMedCrossRef Wakamiya M, Matsuura T, Liu Y, Schuster GC, Gao R, Xu W et al (2006) The role of ataxin 10 in the pathogenesis of spinocerebellar ataxia type 10. Neurology 67:607–613PubMedCrossRef
19.
Zurück zum Zitat Daughters RS, Tuttle DL, Gao W, Ikeda Y, Moseley ML, Ebner TJ et al (2009) RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet 5:e1000600PubMedCrossRef Daughters RS, Tuttle DL, Gao W, Ikeda Y, Moseley ML, Ebner TJ et al (2009) RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet 5:e1000600PubMedCrossRef
20.
Zurück zum Zitat Ikeda Y, Dick KA, Weatherspoon MR, Gincel D, Armbrust KR, Dalton JC et al (2006) Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet 38:184–190PubMedCrossRef Ikeda Y, Dick KA, Weatherspoon MR, Gincel D, Armbrust KR, Dalton JC et al (2006) Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet 38:184–190PubMedCrossRef
21.
Zurück zum Zitat Houlden H, Johnson J, Gardner-Thorpe C, Lashley T, Hernandez D, Worth P et al (2007) Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet 39:1434–1436PubMedCrossRef Houlden H, Johnson J, Gardner-Thorpe C, Lashley T, Hernandez D, Worth P et al (2007) Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet 39:1434–1436PubMedCrossRef
22.
Zurück zum Zitat Waters MF, Minassian NA, Stevanin G, Figueroa KP, Bannister JP, Nolte D et al (2006) Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet 38:447–451PubMedCrossRef Waters MF, Minassian NA, Stevanin G, Figueroa KP, Bannister JP, Nolte D et al (2006) Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet 38:447–451PubMedCrossRef
23.
Zurück zum Zitat Chen DH, Brkanac Z, Verlinde CL, Tan XJ, Bylenok L, Nochlin D et al (2003) Missense mutations in the regulatory domain of PKCgamma: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet 72:839–849PubMedCrossRef Chen DH, Brkanac Z, Verlinde CL, Tan XJ, Bylenok L, Nochlin D et al (2003) Missense mutations in the regulatory domain of PKCgamma: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet 72:839–849PubMedCrossRef
24.
Zurück zum Zitat Yabe I, Sasaki H, Chen DH, Raskind WH, Bird TD, Yamashita I et al (2003) Spinocerebellar ataxia type 14 caused by a mutation in protein kinase C gamma. Arch Neurol 60:1749–1751PubMedCrossRef Yabe I, Sasaki H, Chen DH, Raskind WH, Bird TD, Yamashita I et al (2003) Spinocerebellar ataxia type 14 caused by a mutation in protein kinase C gamma. Arch Neurol 60:1749–1751PubMedCrossRef
25.
Zurück zum Zitat van de Leemput J, Chandran J, Knight MA, Holtzclaw LA, Scholz S, Cookson MR et al (2007) Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet 3:e108PubMedCrossRef van de Leemput J, Chandran J, Knight MA, Holtzclaw LA, Scholz S, Cookson MR et al (2007) Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet 3:e108PubMedCrossRef
26.
Zurück zum Zitat van Swieten JC, Brusse E, de Graaf BM, Krieger E, van de Graaf R, de Koning I et al (2003) A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebral ataxia. Am J Hum Genet 72:191–199PubMedCrossRef van Swieten JC, Brusse E, de Graaf BM, Krieger E, van de Graaf R, de Koning I et al (2003) A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebral ataxia. Am J Hum Genet 72:191–199PubMedCrossRef
27.
Zurück zum Zitat Maltecca F, Magnoni R, Cerri F, Cox GA, Quattrini A, Casari G (2009) Haploinsufficiency of AFG3L2, the gene responsible for spinocerebellar ataxia type 28, causes mitochondria-mediated Purkinje cell dark degeneration. J Neurosci 29:9244–9254PubMedCrossRef Maltecca F, Magnoni R, Cerri F, Cox GA, Quattrini A, Casari G (2009) Haploinsufficiency of AFG3L2, the gene responsible for spinocerebellar ataxia type 28, causes mitochondria-mediated Purkinje cell dark degeneration. J Neurosci 29:9244–9254PubMedCrossRef
28.
Zurück zum Zitat Zoghbi HY, Orr HT (2000) Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23:217–247PubMedCrossRef Zoghbi HY, Orr HT (2000) Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23:217–247PubMedCrossRef
29.
Zurück zum Zitat Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10:S10–S17PubMedCrossRef Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10:S10–S17PubMedCrossRef
30.
Zurück zum Zitat Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 19:148–154PubMedCrossRef Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 19:148–154PubMedCrossRef
31.
Zurück zum Zitat McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J et al (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9:2197–2202PubMedCrossRef McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J et al (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9:2197–2202PubMedCrossRef
32.
Zurück zum Zitat Schmidt T, Lindenberg KS, Krebs A, Schols L, Laccone F, Herms J et al (2002) Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 51:302–310PubMedCrossRef Schmidt T, Lindenberg KS, Krebs A, Schols L, Laccone F, Herms J et al (2002) Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 51:302–310PubMedCrossRef
33.
Zurück zum Zitat Chai Y, Berke SS, Cohen RE, Paulson HL (2004) Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem 279:3605–3611PubMedCrossRef Chai Y, Berke SS, Cohen RE, Paulson HL (2004) Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem 279:3605–3611PubMedCrossRef
34.
Zurück zum Zitat Park Y, Hong S, Kim SJ, Kang S (2005) Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product. Mol Cells 19:23–30PubMed Park Y, Hong S, Kim SJ, Kang S (2005) Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product. Mol Cells 19:23–30PubMed
35.
Zurück zum Zitat Mao Y, Senic-Matuglia F, Di Fiore PP, Polo S, Hodsdon ME, De Camilli P (2005) Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. Proc Natl Acad Sci USA 102:12700–12705PubMedCrossRef Mao Y, Senic-Matuglia F, Di Fiore PP, Polo S, Hodsdon ME, De Camilli P (2005) Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. Proc Natl Acad Sci USA 102:12700–12705PubMedCrossRef
36.
Zurück zum Zitat Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM (2004) Caspase activation inhibits proteasome function during apoptosis. Mol Cell 14:81–93PubMedCrossRef Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM (2004) Caspase activation inhibits proteasome function during apoptosis. Mol Cell 14:81–93PubMedCrossRef
37.
Zurück zum Zitat Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT et al (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10:1511–1518PubMedCrossRef Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT et al (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10:1511–1518PubMedCrossRef
38.
39.
Zurück zum Zitat Sakahira H, Breuer P, Hayer-Hartl MK, Hartl FU (2002) Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc Nat Acad Sci USA 99:16412–16418PubMedCrossRef Sakahira H, Breuer P, Hayer-Hartl MK, Hartl FU (2002) Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc Nat Acad Sci USA 99:16412–16418PubMedCrossRef
40.
Zurück zum Zitat He C, Klionsky DJ (2009) Regulation Mechanisms and Signaling Pathways of Autophagy. Annu Rev Genet (in press) He C, Klionsky DJ (2009) Regulation Mechanisms and Signaling Pathways of Autophagy. Annu Rev Genet (in press)
41.
Zurück zum Zitat Iwata A, Christianson JC, Bucci M, Ellerby LM, Nukina N, Forno LS et al (2005) Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Nat Acad Sci USA 102:13135–13140PubMedCrossRef Iwata A, Christianson JC, Bucci M, Ellerby LM, Nukina N, Forno LS et al (2005) Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Nat Acad Sci USA 102:13135–13140PubMedCrossRef
42.
Zurück zum Zitat Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG et al (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36:585–595PubMedCrossRef Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG et al (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36:585–595PubMedCrossRef
43.
Zurück zum Zitat Helmlinger D, Tora L, Devys D (2006) Transcriptional alterations and chromatin remodeling in polyglutamine diseases. Trends Genet 22:562–570PubMedCrossRef Helmlinger D, Tora L, Devys D (2006) Transcriptional alterations and chromatin remodeling in polyglutamine diseases. Trends Genet 22:562–570PubMedCrossRef
44.
Zurück zum Zitat Matilla A, Koshy BT, Cummings CJ, Isobe T, Orr HT, Zoghbi HY (1997) The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 389:974–978PubMedCrossRef Matilla A, Koshy BT, Cummings CJ, Isobe T, Orr HT, Zoghbi HY (1997) The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 389:974–978PubMedCrossRef
45.
Zurück zum Zitat Okazawa H, Rich T, Chang A, Lin X, Waragai M, Kajikawa M et al (2002) Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 34:701–713PubMedCrossRef Okazawa H, Rich T, Chang A, Lin X, Waragai M, Kajikawa M et al (2002) Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 34:701–713PubMedCrossRef
46.
Zurück zum Zitat Tsai CC, Kao HY, Mitzutani A, Banayo E, Rajan H, McKeown M et al (2004) Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Nat Acad Sci USA 101:4047–4052PubMedCrossRef Tsai CC, Kao HY, Mitzutani A, Banayo E, Rajan H, McKeown M et al (2004) Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Nat Acad Sci USA 101:4047–4052PubMedCrossRef
47.
Zurück zum Zitat Mizutani A, Wang L, Rajan H, Vig PJ, Alaynick WA, Thaler JP et al (2005) Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1. EMBO J 24:3339–3351PubMedCrossRef Mizutani A, Wang L, Rajan H, Vig PJ, Alaynick WA, Thaler JP et al (2005) Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1. EMBO J 24:3339–3351PubMedCrossRef
48.
Zurück zum Zitat Tsuda H, Jafar-Nejad H, Patel AJ, Sun Y, Chen HK, Rose MF et al (2005) The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/senseless proteins. Cell 122:633–644PubMedCrossRef Tsuda H, Jafar-Nejad H, Patel AJ, Sun Y, Chen HK, Rose MF et al (2005) The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/senseless proteins. Cell 122:633–644PubMedCrossRef
49.
Zurück zum Zitat Lam YC, Bowman AB, Jafar-Nejad P, Lim J, Richman R, Fryer JD et al (2006) ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127:1335–1347PubMedCrossRef Lam YC, Bowman AB, Jafar-Nejad P, Lim J, Richman R, Fryer JD et al (2006) ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127:1335–1347PubMedCrossRef
50.
Zurück zum Zitat Serra HG, Duvick L, Zu T, Carlson K, Stevens S, Jorgensen N et al (2006) RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell 127:697–708PubMedCrossRef Serra HG, Duvick L, Zu T, Carlson K, Stevens S, Jorgensen N et al (2006) RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell 127:697–708PubMedCrossRef
51.
Zurück zum Zitat Goold R, Hubank M, Hunt A, Holton J, Menon RP, Revesz T et al (2007) Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Hum Mol Genet 16:2122–2134PubMedCrossRef Goold R, Hubank M, Hunt A, Holton J, Menon RP, Revesz T et al (2007) Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Hum Mol Genet 16:2122–2134PubMedCrossRef
52.
Zurück zum Zitat Matilla-Dueñas A, Goold R, Giunti P (2008) Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum 7:106–114PubMedCrossRef Matilla-Dueñas A, Goold R, Giunti P (2008) Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum 7:106–114PubMedCrossRef
53.
Zurück zum Zitat Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, Naruse S et al (2000) Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 26:29–36PubMedCrossRef Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, Naruse S et al (2000) Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 26:29–36PubMedCrossRef
54.
Zurück zum Zitat Li F, Macfarlan T, Pittman RN, Chakravarti D (2002) Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem 277:45004–45012PubMedCrossRef Li F, Macfarlan T, Pittman RN, Chakravarti D (2002) Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem 277:45004–45012PubMedCrossRef
55.
Zurück zum Zitat Zhang S, Xu L, Lee J, Xu T (2002) Drosophila atrophin homolog functions as a transcriptional corepressor in multiple developmental processes. Cell 108:45–56PubMedCrossRef Zhang S, Xu L, Lee J, Xu T (2002) Drosophila atrophin homolog functions as a transcriptional corepressor in multiple developmental processes. Cell 108:45–56PubMedCrossRef
56.
Zurück zum Zitat Helmlinger D, Hardy S, Sasorith S, Klein F, Robert F, Weber C et al (2004) Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet 13:1257–1265PubMedCrossRef Helmlinger D, Hardy S, Sasorith S, Klein F, Robert F, Weber C et al (2004) Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet 13:1257–1265PubMedCrossRef
57.
Zurück zum Zitat Friedman MJ, Shah AG, Fang ZH, Ward EG, Warren ST, Li S et al (2007) Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci 10:1519–1528PubMedCrossRef Friedman MJ, Shah AG, Fang ZH, Ward EG, Warren ST, Li S et al (2007) Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci 10:1519–1528PubMedCrossRef
58.
Zurück zum Zitat Matilla A, Radrizzani M (2005) The Anp32 family of proteins containing leucine-rich repeats. Cerebellum 4:7–18PubMedCrossRef Matilla A, Radrizzani M (2005) The Anp32 family of proteins containing leucine-rich repeats. Cerebellum 4:7–18PubMedCrossRef
59.
Zurück zum Zitat La Spada AR, Fu Y, Sopher BL, Libby RT, Wang X, Li LY et al (2001) Polyglutamine-expanded ataxin-7 antagonizes crx function and induces cone-rod dystrophy in a mouse model of sca7. Neuron 31:913–927PubMedCrossRef La Spada AR, Fu Y, Sopher BL, Libby RT, Wang X, Li LY et al (2001) Polyglutamine-expanded ataxin-7 antagonizes crx function and induces cone-rod dystrophy in a mouse model of sca7. Neuron 31:913–927PubMedCrossRef
60.
Zurück zum Zitat Kouzarides T (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19:1176–1179PubMedCrossRef Kouzarides T (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19:1176–1179PubMedCrossRef
61.
Zurück zum Zitat Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL et al (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739–743PubMedCrossRef Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL et al (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739–743PubMedCrossRef
62.
Zurück zum Zitat McCampbell A, Taye AA, Whitty L, Penney E, Steffan JS, Fischbeck KH (2001) Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Nat Acad Sci USA 98:15179–15184PubMedCrossRef McCampbell A, Taye AA, Whitty L, Penney E, Steffan JS, Fischbeck KH (2001) Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Nat Acad Sci USA 98:15179–15184PubMedCrossRef
63.
Zurück zum Zitat Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E et al (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Nat Acad Sci USA 100:2041–2046PubMedCrossRef Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E et al (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Nat Acad Sci USA 100:2041–2046PubMedCrossRef
64.
Zurück zum Zitat Clark HB, Burright EN, Yunis WS, Larson S, Wilcox C, Hartman B et al (1997) Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J Neurosci 17:7385–7395PubMed Clark HB, Burright EN, Yunis WS, Larson S, Wilcox C, Hartman B et al (1997) Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J Neurosci 17:7385–7395PubMed
65.
Zurück zum Zitat Serra HG, Byam CE, Lande JD, Tousey SK, Zoghbi HY, Orr HT (2004) Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum Mol Genet 13:2535–2543PubMedCrossRef Serra HG, Byam CE, Lande JD, Tousey SK, Zoghbi HY, Orr HT (2004) Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum Mol Genet 13:2535–2543PubMedCrossRef
66.
Zurück zum Zitat Ichise T, Kano M, Hashimoto K, Yanagihara D, Nakao K, Shigemoto R et al (2000) mGluR1 in cerebellar Purkinje cells essential for long-term depression, synapse elimination, and motor coordination. Science 288:1832–1835PubMedCrossRef Ichise T, Kano M, Hashimoto K, Yanagihara D, Nakao K, Shigemoto R et al (2000) mGluR1 in cerebellar Purkinje cells essential for long-term depression, synapse elimination, and motor coordination. Science 288:1832–1835PubMedCrossRef
67.
Zurück zum Zitat Ikeda Y, Daughters RS, Ranum LP (2008) Bidirectional expression of the SCA8 expansion mutation: one mutation, two genes. Cerebellum 7:150–158PubMedCrossRef Ikeda Y, Daughters RS, Ranum LP (2008) Bidirectional expression of the SCA8 expansion mutation: one mutation, two genes. Cerebellum 7:150–158PubMedCrossRef
68.
Zurück zum Zitat Worth PF, Houlden H, Giunti P, Davis MB, Wood NW (2000) Large, expanded repeats in SCA8 are not confined to patients with cerebellar ataxia. Nat Genet 24:214–215PubMedCrossRef Worth PF, Houlden H, Giunti P, Davis MB, Wood NW (2000) Large, expanded repeats in SCA8 are not confined to patients with cerebellar ataxia. Nat Genet 24:214–215PubMedCrossRef
69.
Zurück zum Zitat Corral J, Genis D, Banchs I, San Nicolas H, Armstrong J, Volpini V (2005) Giant SCA8 alleles in nine children whose mother has two moderately large ones. Ann Neurol 57:549–553PubMedCrossRef Corral J, Genis D, Banchs I, San Nicolas H, Armstrong J, Volpini V (2005) Giant SCA8 alleles in nine children whose mother has two moderately large ones. Ann Neurol 57:549–553PubMedCrossRef
70.
Zurück zum Zitat Lin X, Antalffy B, Kang D, Orr HT, Zoghbi HY (2000) Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci 3:157–163PubMedCrossRef Lin X, Antalffy B, Kang D, Orr HT, Zoghbi HY (2000) Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci 3:157–163PubMedCrossRef
71.
Zurück zum Zitat Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP et al (2009) Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci 29:9148–9162PubMedCrossRef Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP et al (2009) Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci 29:9148–9162PubMedCrossRef
72.
Zurück zum Zitat Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C et al (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 15:62–69PubMedCrossRef Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C et al (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 15:62–69PubMedCrossRef
73.
Zurück zum Zitat Pietrobon D (2002) Calcium channels and channelopathies of the central nervous system. Mol Neurobiol 25:31–50PubMedCrossRef Pietrobon D (2002) Calcium channels and channelopathies of the central nervous system. Mol Neurobiol 25:31–50PubMedCrossRef
74.
Zurück zum Zitat Saegusa H, Wakamori M, Matsuda Y, Wang J, Mori Y, Zong S et al (2007) Properties of human Cav2.1 channel with a spinocerebellar ataxia type 6 mutation expressed in Purkinje cells. Mol Cell Neurosci 34:261–270PubMedCrossRef Saegusa H, Wakamori M, Matsuda Y, Wang J, Mori Y, Zong S et al (2007) Properties of human Cav2.1 channel with a spinocerebellar ataxia type 6 mutation expressed in Purkinje cells. Mol Cell Neurosci 34:261–270PubMedCrossRef
75.
Zurück zum Zitat Adachi N, Kobayashi T, Takahashi H, Kawasaki T, Shirai Y, Ueyama T et al (2008) Enzymological analysis of mutant protein kinase Cgamma causing spinocerebellar ataxia type 14 and dysfunction in Ca2+ homeostasis. J Biol Chem 283:19854–19863PubMedCrossRef Adachi N, Kobayashi T, Takahashi H, Kawasaki T, Shirai Y, Ueyama T et al (2008) Enzymological analysis of mutant protein kinase Cgamma causing spinocerebellar ataxia type 14 and dysfunction in Ca2+ homeostasis. J Biol Chem 283:19854–19863PubMedCrossRef
76.
Zurück zum Zitat Lipinski MM, Yuan J (2004) Mechanisms of cell death in polyglutamine expansion diseases. Curr Opin Pharm 4:85–90CrossRef Lipinski MM, Yuan J (2004) Mechanisms of cell death in polyglutamine expansion diseases. Curr Opin Pharm 4:85–90CrossRef
77.
Zurück zum Zitat Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22:623–633PubMedCrossRef Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22:623–633PubMedCrossRef
78.
Zurück zum Zitat Chou AH, Yeh TH, Kuo YL, Kao YC, Jou MJ, Hsu CY et al (2006) Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-x(L). Neurobiol Dis 21:333–345PubMedCrossRef Chou AH, Yeh TH, Kuo YL, Kao YC, Jou MJ, Hsu CY et al (2006) Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-x(L). Neurobiol Dis 21:333–345PubMedCrossRef
79.
Zurück zum Zitat Wang HL, Yeh TH, Chou AH, Kuo YL, Luo LJ, He CY et al (2006) Polyglutamine-expanded ataxin-7 activates mitochondrial apoptotic pathway of cerebellar neurons by upregulating Bax and downregulating Bcl-x(L). Cell Signal 18:541–552PubMedCrossRef Wang HL, Yeh TH, Chou AH, Kuo YL, Luo LJ, He CY et al (2006) Polyglutamine-expanded ataxin-7 activates mitochondrial apoptotic pathway of cerebellar neurons by upregulating Bax and downregulating Bcl-x(L). Cell Signal 18:541–552PubMedCrossRef
80.
Zurück zum Zitat Chen HK, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, Fernandez MH et al (2003) Interaction of Akt-phosphorylated ataxin-1 with 14–3–3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113:457–468PubMedCrossRef Chen HK, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, Fernandez MH et al (2003) Interaction of Akt-phosphorylated ataxin-1 with 14–3–3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113:457–468PubMedCrossRef
81.
Zurück zum Zitat van de Warrenburg BP, Hendriks H, Durr A, van Zuijlen MC, Stevanin G, Camuzat A et al (2005) Age at onset variance analysis in spinocerebellar ataxias: a study in a Dutch–French cohort. Ann Neurol 57:505–512PubMedCrossRef van de Warrenburg BP, Hendriks H, Durr A, van Zuijlen MC, Stevanin G, Camuzat A et al (2005) Age at onset variance analysis in spinocerebellar ataxias: a study in a Dutch–French cohort. Ann Neurol 57:505–512PubMedCrossRef
82.
Zurück zum Zitat Albrecht M, Golatta M, Wullner U, Lengauer T (2004) Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem 271:3155–3170PubMedCrossRef Albrecht M, Golatta M, Wullner U, Lengauer T (2004) Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem 271:3155–3170PubMedCrossRef
83.
Zurück zum Zitat He W, Parker R (2000) Functions of Lsm proteins in mRNA degradation and splicing. Curr Opin Cell Biol 12:346–350PubMedCrossRef He W, Parker R (2000) Functions of Lsm proteins in mRNA degradation and splicing. Curr Opin Cell Biol 12:346–350PubMedCrossRef
84.
Zurück zum Zitat Shibata H, Huynh DP, Pulst SM (2000) A novel protein with RNA-binding motifs interacts with ataxin-2. Hum Mol Genet 9:1303–1313PubMedCrossRef Shibata H, Huynh DP, Pulst SM (2000) A novel protein with RNA-binding motifs interacts with ataxin-2. Hum Mol Genet 9:1303–1313PubMedCrossRef
85.
Zurück zum Zitat Jin Y, Suzuki H, Maegawa S, Endo H, Sugano S, Hashimoto K et al (2003) A vertebrate RNA-binding protein Fox-1 regulates tissue-specific splicing via the pentanucleotide GCAUG. EMBO J 22:905–912PubMedCrossRef Jin Y, Suzuki H, Maegawa S, Endo H, Sugano S, Hashimoto K et al (2003) A vertebrate RNA-binding protein Fox-1 regulates tissue-specific splicing via the pentanucleotide GCAUG. EMBO J 22:905–912PubMedCrossRef
86.
Zurück zum Zitat Matsuura T, Yamagata T, Burgess DL, Rasmussen A, Grewal RP, Watase K et al (2000) Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet 26:191–194PubMedCrossRef Matsuura T, Yamagata T, Burgess DL, Rasmussen A, Grewal RP, Watase K et al (2000) Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet 26:191–194PubMedCrossRef
87.
Zurück zum Zitat Lin X, Ashizawa T (2005) Recent progress in spinocerebellar ataxia type-10 (SCA10). Cerebellum 4:37–42PubMedCrossRef Lin X, Ashizawa T (2005) Recent progress in spinocerebellar ataxia type-10 (SCA10). Cerebellum 4:37–42PubMedCrossRef
88.
Zurück zum Zitat Coates JC (2003) Armadillo repeat proteins: beyond the animal kingdom. Trends Cell Biol 13:463–471PubMedCrossRef Coates JC (2003) Armadillo repeat proteins: beyond the animal kingdom. Trends Cell Biol 13:463–471PubMedCrossRef
89.
Zurück zum Zitat Sontag E (2001) Protein phosphatase 2A: the Trojan horse of cellular signaling. Cell Signal 13:7–16PubMedCrossRef Sontag E (2001) Protein phosphatase 2A: the Trojan horse of cellular signaling. Cell Signal 13:7–16PubMedCrossRef
90.
Zurück zum Zitat Lim J, Lu KP (2005) Pinning down phosphorylated tau and tauopathies. Biochim Biophys Acta 1739:311–322PubMed Lim J, Lu KP (2005) Pinning down phosphorylated tau and tauopathies. Biochim Biophys Acta 1739:311–322PubMed
92.
Zurück zum Zitat Newton AC (2001) Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 101:2353–2364PubMedCrossRef Newton AC (2001) Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 101:2353–2364PubMedCrossRef
93.
Zurück zum Zitat Schrenk K, Kapfhammer JP, Metzger F (2002) Altered dendritic development of cerebellar Purkinje cells in slice cultures from protein kinase Cgamma-deficient mice. Neuroscience 110:675–689PubMedCrossRef Schrenk K, Kapfhammer JP, Metzger F (2002) Altered dendritic development of cerebellar Purkinje cells in slice cultures from protein kinase Cgamma-deficient mice. Neuroscience 110:675–689PubMedCrossRef
94.
Zurück zum Zitat Abeliovich A, Paylor R, Chen C, Kim JJ, Wehner JM, Tonegawa S (1993) PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning. Cell 75:1263–1271PubMedCrossRef Abeliovich A, Paylor R, Chen C, Kim JJ, Wehner JM, Tonegawa S (1993) PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning. Cell 75:1263–1271PubMedCrossRef
95.
Zurück zum Zitat Verbeek DS, Goedhart J, Bruinsma L, Sinke RJ, Reits EA (2008) PKC gamma mutations in spinocerebellar ataxia type 14 affect C1 domain accessibility and kinase activity leading to aberrant MAPK signaling. J Cell Sci 121:2339–2349PubMedCrossRef Verbeek DS, Goedhart J, Bruinsma L, Sinke RJ, Reits EA (2008) PKC gamma mutations in spinocerebellar ataxia type 14 affect C1 domain accessibility and kinase activity leading to aberrant MAPK signaling. J Cell Sci 121:2339–2349PubMedCrossRef
96.
Zurück zum Zitat Wang Q, Bardgett ME, Wong M, Wozniak DF, Lou J, McNeil BD et al (2002) Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14. Neuron 35:25–38PubMedCrossRef Wang Q, Bardgett ME, Wong M, Wozniak DF, Lou J, McNeil BD et al (2002) Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14. Neuron 35:25–38PubMedCrossRef
97.
Zurück zum Zitat Shakkottai VG, Xiao M, Xu L, Wong M, Nerbonne JM, Ornitz DM et al (2009) FGF14 regulates the intrinsic excitability of cerebellar Purkinje neurons. Neurobiol Dis 33:81–88PubMedCrossRef Shakkottai VG, Xiao M, Xu L, Wong M, Nerbonne JM, Ornitz DM et al (2009) FGF14 regulates the intrinsic excitability of cerebellar Purkinje neurons. Neurobiol Dis 33:81–88PubMedCrossRef
98.
Zurück zum Zitat Ishikawa K, Toru S, Tsunemi T, Li M, Kobayashi K, Yokota T et al (2005) An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5′ untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains. Am J Hum Genet 77:280–296PubMedCrossRef Ishikawa K, Toru S, Tsunemi T, Li M, Kobayashi K, Yokota T et al (2005) An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5′ untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains. Am J Hum Genet 77:280–296PubMedCrossRef
99.
Zurück zum Zitat Flanigan K, Gardner K, Alderson K, Galster B, Otterud B, Leppert MF et al (1996) Autosomal dominant spinocerebellar ataxia with sensory axonal neuropathy (SCA4): clinical description and genetic localization to chromosome 16q22.1. Am J Hum Genet 59:392–399PubMed Flanigan K, Gardner K, Alderson K, Galster B, Otterud B, Leppert MF et al (1996) Autosomal dominant spinocerebellar ataxia with sensory axonal neuropathy (SCA4): clinical description and genetic localization to chromosome 16q22.1. Am J Hum Genet 59:392–399PubMed
101.
Zurück zum Zitat Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, Carrillo-Fumero R (2009) Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord 24:1111–1124PubMedCrossRef Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, Carrillo-Fumero R (2009) Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord 24:1111–1124PubMedCrossRef
102.
Zurück zum Zitat Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R et al (2007) Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 4:e182PubMedCrossRef Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R et al (2007) Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 4:e182PubMedCrossRef
103.
Zurück zum Zitat Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT et al (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10:816–820PubMedCrossRef Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT et al (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10:816–820PubMedCrossRef
104.
Zurück zum Zitat Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6:11–22PubMedCrossRef Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6:11–22PubMedCrossRef
105.
Zurück zum Zitat Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM (2000) Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 9:2811–2820PubMedCrossRef Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM (2000) Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 9:2811–2820PubMedCrossRef
106.
Zurück zum Zitat Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N et al (2000) Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Nat Acad Sci USA 97:6739–6744PubMedCrossRef Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N et al (2000) Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Nat Acad Sci USA 97:6739–6744PubMedCrossRef
107.
Zurück zum Zitat Sanchez I, Mahlke C, Yuan J (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421:373–379PubMedCrossRef Sanchez I, Mahlke C, Yuan J (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421:373–379PubMedCrossRef
108.
Zurück zum Zitat Yoshida H, Yoshizawa T, Shibasaki F, Shoji S, Kanazawa I (2002) Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol Dis 10:88–99PubMedCrossRef Yoshida H, Yoshizawa T, Shibasaki F, Shoji S, Kanazawa I (2002) Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol Dis 10:88–99PubMedCrossRef
109.
Zurück zum Zitat Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H et al (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10:148–154PubMedCrossRef Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H et al (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10:148–154PubMedCrossRef
110.
Zurück zum Zitat Heiser V, Engemann S, Brocker W, Dunkel I, Boeddrich A, Waelter S et al (2002) Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Nat Acad Sci USA 99:16400–16406PubMedCrossRef Heiser V, Engemann S, Brocker W, Dunkel I, Boeddrich A, Waelter S et al (2002) Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Nat Acad Sci USA 99:16400–16406PubMedCrossRef
111.
Zurück zum Zitat Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M et al (2005) A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Nat Acad Sci USA 102:892–897PubMedCrossRef Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M et al (2005) A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Nat Acad Sci USA 102:892–897PubMedCrossRef
112.
Zurück zum Zitat Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10:402–405PubMedCrossRef Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10:402–405PubMedCrossRef
113.
Zurück zum Zitat Rimoldi M, Servadio A, Zimarino V (2001) Analysis of heat shock transcription factor for suppression of polyglutamine toxicity. Brain Res Bull 56:353–362PubMedCrossRef Rimoldi M, Servadio A, Zimarino V (2001) Analysis of heat shock transcription factor for suppression of polyglutamine toxicity. Brain Res Bull 56:353–362PubMedCrossRef
114.
Zurück zum Zitat Mosser DD, Morimoto RI (2004) Molecular chaperones and the stress of oncogenesis. Oncogene 23:2907–2918PubMedCrossRef Mosser DD, Morimoto RI (2004) Molecular chaperones and the stress of oncogenesis. Oncogene 23:2907–2918PubMedCrossRef
115.
Zurück zum Zitat Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW et al (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22:8942–8950PubMed Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW et al (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22:8942–8950PubMed
116.
Zurück zum Zitat Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R et al (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8:143–149PubMedCrossRef Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R et al (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8:143–149PubMedCrossRef
117.
118.
Zurück zum Zitat Ryu H, Rosas HD, Hersch SM, Ferrante RJ (2005) The therapeutic role of creatine in Huntington's disease. Pharmacol Ther 108:193–207PubMedCrossRef Ryu H, Rosas HD, Hersch SM, Ferrante RJ (2005) The therapeutic role of creatine in Huntington's disease. Pharmacol Ther 108:193–207PubMedCrossRef
119.
Zurück zum Zitat Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC (2002) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Nat Acad Sci USA 99:10671–10676PubMedCrossRef Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC (2002) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Nat Acad Sci USA 99:10671–10676PubMedCrossRef
120.
Zurück zum Zitat Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM et al (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399:263–267PubMedCrossRef Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM et al (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399:263–267PubMedCrossRef
121.
Zurück zum Zitat Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S et al (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797–801PubMedCrossRef Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S et al (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797–801PubMedCrossRef
122.
Zurück zum Zitat Lesort M, Lee M, Tucholski J, Johnson GV (2003) Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 278:3825–3830PubMedCrossRef Lesort M, Lee M, Tucholski J, Johnson GV (2003) Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 278:3825–3830PubMedCrossRef
123.
Zurück zum Zitat Gauthier S (2009) Dimebon improves cognitive function in people with mild to moderate Alzheimer's disease. Evid Based Ment Health 12:21PubMedCrossRef Gauthier S (2009) Dimebon improves cognitive function in people with mild to moderate Alzheimer's disease. Evid Based Ment Health 12:21PubMedCrossRef
124.
Zurück zum Zitat Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009) Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev CD006455 Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009) Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev CD006455
125.
Zurück zum Zitat Bordet T, Buisson B, Michaud M, Drouot C, Galea P, Delaage P et al (2007) Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 322:709–720PubMedCrossRef Bordet T, Buisson B, Michaud M, Drouot C, Galea P, Delaage P et al (2007) Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 322:709–720PubMedCrossRef
126.
Zurück zum Zitat Strupp M, Kalla R, Glasauer S, Wagner J, Hufner K, Jahn K et al (2008) Aminopyridines for the treatment of cerebellar and ocular motor disorders. Prog Brain Res 171:535–541PubMedCrossRef Strupp M, Kalla R, Glasauer S, Wagner J, Hufner K, Jahn K et al (2008) Aminopyridines for the treatment of cerebellar and ocular motor disorders. Prog Brain Res 171:535–541PubMedCrossRef
127.
Zurück zum Zitat Dokmanovic M, Marks PA (2005) Prospects: Histone deacetylase inhibitors. J Cell Biochem 96:293–304PubMedCrossRef Dokmanovic M, Marks PA (2005) Prospects: Histone deacetylase inhibitors. J Cell Biochem 96:293–304PubMedCrossRef
128.
Zurück zum Zitat Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R et al (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 105:15564–15569PubMedCrossRef Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R et al (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 105:15564–15569PubMedCrossRef
129.
Zurück zum Zitat Naoi M, Maruyama W, Yi H, Inaba K, Akao Y, Shamoto-Nagai M (2009) Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J Neural Transm (in press) Naoi M, Maruyama W, Yi H, Inaba K, Akao Y, Shamoto-Nagai M (2009) Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J Neural Transm (in press)
130.
Zurück zum Zitat Gatchel JR, Watase K, Thaller C, Carson JP, Jafar-Nejad P, Shaw C et al (2008) The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7. Proc Nat Acad Sci USA 105:1291–1296PubMedCrossRef Gatchel JR, Watase K, Thaller C, Carson JP, Jafar-Nejad P, Shaw C et al (2008) The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7. Proc Nat Acad Sci USA 105:1291–1296PubMedCrossRef
131.
Zurück zum Zitat Fernandez AM, Carro EM, Lopez-Lopez C, Torres-Aleman I (2005) Insulin-like growth factor I treatment for cerebellar ataxia: Addressing a common pathway in the pathological cascade? Brain Res Rev 50:134–141PubMedCrossRef Fernandez AM, Carro EM, Lopez-Lopez C, Torres-Aleman I (2005) Insulin-like growth factor I treatment for cerebellar ataxia: Addressing a common pathway in the pathological cascade? Brain Res Rev 50:134–141PubMedCrossRef
132.
Zurück zum Zitat Leinninger GM, Feldman EL (2005) Insulin-like growth factors in the treatment of neurological disease. Endocr Devel 9:135–159CrossRef Leinninger GM, Feldman EL (2005) Insulin-like growth factors in the treatment of neurological disease. Endocr Devel 9:135–159CrossRef
133.
Zurück zum Zitat Gage FH (2002) Neurogenesis in the adult brain. J Neurosci 22:612–613PubMed Gage FH (2002) Neurogenesis in the adult brain. J Neurosci 22:612–613PubMed
134.
Zurück zum Zitat Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717–1720PubMedCrossRef Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717–1720PubMedCrossRef
135.
Zurück zum Zitat Schmitz-Hubsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Sacca F et al (2008) SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 71:486–492PubMedCrossRef Schmitz-Hubsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Sacca F et al (2008) SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 71:486–492PubMedCrossRef
136.
Zurück zum Zitat Lastres-Becker I, Rub U, Auburger G (2008) Spinocerebellar ataxia 2 (SCA2). Cerebellum 7:115–124PubMedCrossRef Lastres-Becker I, Rub U, Auburger G (2008) Spinocerebellar ataxia 2 (SCA2). Cerebellum 7:115–124PubMedCrossRef
137.
Zurück zum Zitat Garden GA, La Spada AR (2008) Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum 7:138–149PubMedCrossRef Garden GA, La Spada AR (2008) Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum 7:138–149PubMedCrossRef
138.
Zurück zum Zitat Higgins JJ, Pho LT, Ide SE, Nee LE, Polymeropoulos MH (1997) Evidence for a new spinocerebellar ataxia locus. Mov Disord 12:412–417PubMedCrossRef Higgins JJ, Pho LT, Ide SE, Nee LE, Polymeropoulos MH (1997) Evidence for a new spinocerebellar ataxia locus. Mov Disord 12:412–417PubMedCrossRef
139.
Zurück zum Zitat Johnson J, Wood N, Giunti P, Houlden H (2008) Clinical and genetic analysis of spinocerebellar ataxia type 11. Cerebellum 7:159–164PubMedCrossRef Johnson J, Wood N, Giunti P, Houlden H (2008) Clinical and genetic analysis of spinocerebellar ataxia type 11. Cerebellum 7:159–164PubMedCrossRef
140.
Zurück zum Zitat Miyoshi Y, Yamada T, Tanimura M, Taniwaki T, Arakawa K, Ohyagi Y et al (2001) A novel autosomal dominant spinocerebellar ataxia (SCA16) linked to chromosome 8q22.1-24.1. Neurology 57:96–100PubMed Miyoshi Y, Yamada T, Tanimura M, Taniwaki T, Arakawa K, Ohyagi Y et al (2001) A novel autosomal dominant spinocerebellar ataxia (SCA16) linked to chromosome 8q22.1-24.1. Neurology 57:96–100PubMed
141.
Zurück zum Zitat Stevanin G, Brice A (2008) Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4). Cerebellum 7:170–178PubMedCrossRef Stevanin G, Brice A (2008) Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4). Cerebellum 7:170–178PubMedCrossRef
142.
Zurück zum Zitat Devos D, Schraen-Maschke S, Vuillaume I, Dujardin K, Naze P, Willoteaux C et al (2001) Clinical features and genetic analysis of a new form of spinocerebellar ataxia. Neurology 56:234–238PubMed Devos D, Schraen-Maschke S, Vuillaume I, Dujardin K, Naze P, Willoteaux C et al (2001) Clinical features and genetic analysis of a new form of spinocerebellar ataxia. Neurology 56:234–238PubMed
143.
Zurück zum Zitat Verbeek DS, Schelhaas JH, Ippel EF, Beemer FA, Pearson PL, Sinke RJ (2002) Identification of a novel SCA locus (SCA19) in a Dutch autosomal dominant cerebellar ataxia family on chromosome region 1p21–q21. Hum Genet 111:388–393PubMedCrossRef Verbeek DS, Schelhaas JH, Ippel EF, Beemer FA, Pearson PL, Sinke RJ (2002) Identification of a novel SCA locus (SCA19) in a Dutch autosomal dominant cerebellar ataxia family on chromosome region 1p21–q21. Hum Genet 111:388–393PubMedCrossRef
144.
Zurück zum Zitat Schelhaas HJ, van de Warrenburg BP (2005) Clinical, psychological, and genetic characteristics of spinocerebellar ataxia type 19 (SCA19). Cerebellum 4:51–54PubMedCrossRef Schelhaas HJ, van de Warrenburg BP (2005) Clinical, psychological, and genetic characteristics of spinocerebellar ataxia type 19 (SCA19). Cerebellum 4:51–54PubMedCrossRef
145.
Zurück zum Zitat Knight MA, Hernandez D, Diede SJ, Dauwerse HG, Rafferty I, van de Leemput J et al (2008) A duplication at chromosome 11q12.2–11q12.3 is associated with spinocerebellar ataxia type 20. Hum Mol Genet 17:3847–3853PubMedCrossRef Knight MA, Hernandez D, Diede SJ, Dauwerse HG, Rafferty I, van de Leemput J et al (2008) A duplication at chromosome 11q12.2–11q12.3 is associated with spinocerebellar ataxia type 20. Hum Mol Genet 17:3847–3853PubMedCrossRef
146.
Zurück zum Zitat Delplanque J, Devos D, Vuillaume I, De Becdelievre A, Vangelder E, Maurage CA et al (2008) Slowly progressive spinocerebellar ataxia with extrapyramidal signs and mild cognitive impairment (SCA21). Cerebellum 7:179–183PubMedCrossRef Delplanque J, Devos D, Vuillaume I, De Becdelievre A, Vangelder E, Maurage CA et al (2008) Slowly progressive spinocerebellar ataxia with extrapyramidal signs and mild cognitive impairment (SCA21). Cerebellum 7:179–183PubMedCrossRef
147.
Zurück zum Zitat Chung MY, Lu YC, Cheng NC, Soong BW (2003) A novel autosomal dominant spinocerebellar ataxia (SCA22) linked to chromosome 1p21–q23. Brain 126:1293–1299PubMedCrossRef Chung MY, Lu YC, Cheng NC, Soong BW (2003) A novel autosomal dominant spinocerebellar ataxia (SCA22) linked to chromosome 1p21–q23. Brain 126:1293–1299PubMedCrossRef
148.
149.
Zurück zum Zitat Stevanin G, Broussolle E, Streichenberger N, Kopp N, Brice A, Durr A (2005) Spinocerebellar ataxia with sensory neuropathy (SCA25). Cerebellum 4:58–61PubMedCrossRef Stevanin G, Broussolle E, Streichenberger N, Kopp N, Brice A, Durr A (2005) Spinocerebellar ataxia with sensory neuropathy (SCA25). Cerebellum 4:58–61PubMedCrossRef
150.
Zurück zum Zitat Yu GY, Howell MJ, Roller MJ, Xie TD, Gomez CM (2005) Spinocerebellar ataxia type 26 maps to chromosome 19p13.3 adjacent to SCA6. Ann Neurol 57:349–354PubMedCrossRef Yu GY, Howell MJ, Roller MJ, Xie TD, Gomez CM (2005) Spinocerebellar ataxia type 26 maps to chromosome 19p13.3 adjacent to SCA6. Ann Neurol 57:349–354PubMedCrossRef
151.
Zurück zum Zitat Mariotti C, Brusco A, Di Bella D, Cagnoli C, Seri M, Gellera C et al (2008) Spinocerebellar ataxia type 28: a novel autosomal dominant cerebellar ataxia characterized by slow progression and ophthalmoparesis. Cerebellum 7:184–188PubMedCrossRef Mariotti C, Brusco A, Di Bella D, Cagnoli C, Seri M, Gellera C et al (2008) Spinocerebellar ataxia type 28: a novel autosomal dominant cerebellar ataxia characterized by slow progression and ophthalmoparesis. Cerebellum 7:184–188PubMedCrossRef
152.
Zurück zum Zitat Dudding TE, Friend K, Schofield PW, Lee S, Wilkinson IA, Richards RI (2004) Autosomal dominant congenital non-progressive ataxia overlaps with the SCA15 locus. Neurology 63:2288–2292PubMed Dudding TE, Friend K, Schofield PW, Lee S, Wilkinson IA, Richards RI (2004) Autosomal dominant congenital non-progressive ataxia overlaps with the SCA15 locus. Neurology 63:2288–2292PubMed
153.
Zurück zum Zitat Storey E, Bahlo M, Fahey M, Sisson O, Lueck CJ, Gardner RJ (2009) A new dominantly inherited pure cerebellar ataxia, SCA 30. J Neurol Neurosurg Psychiatry 80:408–411PubMedCrossRef Storey E, Bahlo M, Fahey M, Sisson O, Lueck CJ, Gardner RJ (2009) A new dominantly inherited pure cerebellar ataxia, SCA 30. J Neurol Neurosurg Psychiatry 80:408–411PubMedCrossRef
154.
Zurück zum Zitat Tsuji S (2002) Dentatorubral-pallidoluysian atrophy: clinical aspects and molecular genetics. Adv Neurol 89:231–239PubMed Tsuji S (2002) Dentatorubral-pallidoluysian atrophy: clinical aspects and molecular genetics. Adv Neurol 89:231–239PubMed
155.
Zurück zum Zitat Genis D, Ferrer I, Sole JV, Corral J, Volpini V, San Nicolas H et al (2009) A kindred with cerebellar ataxia and thermoanalgesia. J Neurol Neurosurg Psychiatry 80:518–523PubMedCrossRef Genis D, Ferrer I, Sole JV, Corral J, Volpini V, San Nicolas H et al (2009) A kindred with cerebellar ataxia and thermoanalgesia. J Neurol Neurosurg Psychiatry 80:518–523PubMedCrossRef
Metadaten
Titel
Cellular and Molecular Pathways Triggering Neurodegeneration in the Spinocerebellar Ataxias
verfasst von
Antoni Matilla-Dueñas
Ivelisse Sánchez
Marc Corral-Juan
Antoni Dávalos
Ramiro Alvarez
Pilar Latorre
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
The Cerebellum / Ausgabe 2/2010
Print ISSN: 1473-4222
Elektronische ISSN: 1473-4230
DOI
https://doi.org/10.1007/s12311-009-0144-2

Weitere Artikel der Ausgabe 2/2010

The Cerebellum 2/2010 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.